Linked Life Data

17559733

Source:http://linkedlifedata.com/resource/pubmed/id/17559733

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-4-23
pubmed:abstractText
Sitagliptin, an oral, potent, and selective dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated as once-daily monotherapy in a 12-week randomized, double-blind, placebo-controlled, parallel group, dose-ranging study. Additionally, the glycemic response to sitagliptin 100 mg daily was evaluated as a once-daily (100 mg once-daily) or twice-daily (50 mg twice-daily) dosing regimen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1473-4877
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1329-39
pubmed:meshHeading
pubmed-meshheading:17559733-Adult, pubmed-meshheading:17559733-Aged, pubmed-meshheading:17559733-Blood Glucose, pubmed-meshheading:17559733-Diabetes Mellitus, Type 2, pubmed-meshheading:17559733-Dipeptidyl-Peptidase IV Inhibitors, pubmed-meshheading:17559733-Dose-Response Relationship, Drug, pubmed-meshheading:17559733-Double-Blind Method, pubmed-meshheading:17559733-Drug Administration Schedule, pubmed-meshheading:17559733-Drug Dosage Calculations, pubmed-meshheading:17559733-Female, pubmed-meshheading:17559733-Hemoglobin A, Glycosylated, pubmed-meshheading:17559733-Humans, pubmed-meshheading:17559733-Hypoglycemic Agents, pubmed-meshheading:17559733-Male, pubmed-meshheading:17559733-Middle Aged, pubmed-meshheading:17559733-Placebos, pubmed-meshheading:17559733-Pyrazines, pubmed-meshheading:17559733-Treatment Outcome, pubmed-meshheading:17559733-Triazoles
pubmed:year
2007
pubmed:articleTitle
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
pubmed:affiliation
GWT-Technical University, Dresden, Germany.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study